Drug Search Results

Ombrabulin

Alternative Names: ombrabulin, ave-8062, ave8062, ave 8062
Latest Update: 2024-04-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Tubulin Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ombrabulin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Sarcoma

Phase 2: Ovarian Cancer|Non-Small-Cell Lung Cancer

Phase 1: Oncology Solid Tumor Unspecified

Trial	Phase	Trial Status	Disease	Primary Completion Date
TCD11379	P1	Completed	Oncology Solid Tumor Unspecified	2014-10-01
OPSALIN	P2	Completed	Ovarian Cancer	2014-07-01
TCD11270	P1	Completed	Oncology Solid Tumor Unspecified	2013-10-01
2007-003592-39	P3	Completed	Sarcoma	2013-04-17

Recent News Events

Date	Type	Title
04/01/2024	PubMed	Phase I study of ombrabulin in combination with paclitaxel and carboplatin in Japanese patients with advanced solid tumors.
02/21/2024	PubMed	Discovery, synthesis, activities, structure-activity relationships, and clinical development of combretastatins and analogs as anticancer drugs. A comprehensive review.
11/24/2020	PubMed	Anti-Angiogenic Agents in Management of Sarcoma Patients: Overview of Published Trials.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions